University of British Columbia

Myant Corp. acquires mmHg Inc., enhancing its precision medicine approach with mmHg's remote blood pressure monitoring and cardiovascular risk management. This merger aims to improve chronic disease management through AI-enabled, personalized healthcare, leveraging mmHg's software and Myant's textile computing for real-time patient data and better health outcomes.

Myant Corp. acquires mmHg Inc., enhancing its precision medicine capabilities for cardiovascular care. This merger combines Myant's textile computing with mmHg's remote blood pressure monitoring, aiming to improve chronic disease management and patient outcomes through AI-enabled, personalized healthcare solutions.

Dr. Timsy Bhando from McMaster University won a Mitacs award for developing KCB-100, a fungi-based compound with potential to treat dementia, depression, and brain diseases. Supported by Kapoose Creek Bio, her work emphasizes natural drugs over synthetic compounds, aiming to advance neurodegenerative disease treatments.

Hemostemix Inc. applies to up-list on the OTCQB Venture Market to enhance liquidity across USA, Europe, and Canada. Its ACP-01 therapy shows significant efficacy, with 83% of Phase II trial patients experiencing ulcer healing and ischemic rest pain resolution. Cardiac function improved up to 47.1% in cardiomyopathy patients. The therapy targets a vast market, with 236 million suffering from peripheral arterial disease.

Hemostemix's social media campaign for "Your Fountain of Youth"™ regenerative medicine is gaining traction, sharing patient success stories and educating on ACP-01 treatment for cardiovascular diseases. ACP-01, derived from patients' blood, has shown significant improvements in cardiac function and ulcer healing.

AI/ML Innovations Inc. acquires Quantum Sciences Ltd., enhancing AI-driven digital healthcare solutions, particularly in cardiovascular disease. The acquisition leverages Quantum's medical expertise and AI/ML's signal processing capabilities for cardio-focused applications, aiming to improve patient outcomes and medical workflows.

Canada’s Ocean Supercluster announces $3.6M Blue Futures Pathways Program Phase III, aiming to connect Canadian youth with education, funding, and employment in the sustainable blue economy. The program, led by The Students on Ice Foundation, includes partners like the University of British Columbia and focuses on attracting underrepresented youth, integrating Indigenous knowledge, and fostering a socially equitable and economically viable blue economy.

A deep learning model accurately classifies pancreatic ductal adenocarcinoma (PDAC) into molecular subtypes using histopathology images, offering a rapid, cost-effective alternative to molecular assays. Published in the American Journal of Pathology, this approach aims to enhance personalized treatment and patient outcomes, achieving high accuracy across datasets.

Fred Hutchinson Cancer Research Center, founded without a hospital or large endowment, achieved groundbreaking success in bone marrow transplantation, curing blood diseases and advancing cancer research. Overcoming initial skepticism and technical challenges, the center's persistence led to life-saving treatments, inspiring further medical breakthroughs. Today, Fred Hutch is a global leader in cancer and infectious disease research, pioneering precision oncology and vaccine development, with a legacy of tackling complex medical challenges to improve patient outcomes.